Study group for Leiomyoma

Phase-Based Progress Estimates
NYU Langone Health, New York, NY
Leiomyoma+2 More
LIFE program - Other
18 - 65
What conditions do you have?

Study Summary

The study will evaluate a lifestyle, nutrition, and exercise program to assess whether this program is acceptable and feasible for patients..Researchers will examine if the LIFE program can modify fibroid recurrence.

Eligible Conditions

  • Leiomyoma
  • Uterine Fibroids (Leiomyomas)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Leiomyoma

Study Objectives

3 Primary · 0 Secondary · Reporting Duration: Baseline, 6 month, 12 month

12 month visit.
Acceptability of LIFE program as measured by Self report survey
Month 12
Change in fibroid recurrence as measured by standard of care ultrasounds
Change in improvement in quality of life as measured by Quality of Life Scale (QOLS)

Trial Safety

Safety Progress

1 of 3

Other trials for Leiomyoma

Trial Design

1 Treatment Group

Study group
1 of 1
Experimental Treatment

50 Total Participants · 1 Treatment Group

Primary Treatment: Study group · No Placebo Group · N/A

Study group
Experimental Group · 1 Intervention: LIFE program · Intervention Types: Other

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline, 6 month, 12 month
Closest Location: NYU Langone Health · New York, NY
Photo of NYU Langone Health  1Photo of NYU Langone Health  2Photo of NYU Langone Health  3
2020First Recorded Clinical Trial
1 TrialsResearching Leiomyoma
107 CompletedClinical Trials

Eligibility Criteria

Age 18 - 65 · Female Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are aged 18-50, and you are seeking care at the Center for Fibroid Care at NYU.
You have had a procedure or surgery to remove fibroids within the last 3 months and are now considered fibroid free.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.